4.7 Review

Acute severe ulcerative colitis: from pathophysiology to clinical management

Journal

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
Volume 13, Issue 11, Pages 654-664

Publisher

NATURE PORTFOLIO
DOI: 10.1038/nrgastro.2016.116

Keywords

-

Funding

  1. Abbvie
  2. Takeda
  3. Chiesi
  4. Ferring
  5. Falk Pharma
  6. Tillotts Pharma
  7. Vifor Pharma
  8. Sandoz
  9. Janssen
  10. ActoGeniX NV
  11. Amgen
  12. AM-Pharma BV
  13. Boehringer-Ingelheim
  14. Centocor/Janssen Biologics
  15. ChemoCentryx
  16. Cosmo Technologies
  17. Elan/Biogen
  18. EnGene
  19. Ferring Pharmaceuticals
  20. Gilead Sciences
  21. Given Imaging
  22. GlaxoSmithKline
  23. Merck Research Laboratories
  24. Merck Serono
  25. Millenium Pharmaceuticals
  26. Novo Nordisk
  27. NPS Pharmaceuticals
  28. PDL Biopharma
  29. Pfizer
  30. Receptos
  31. Salix Pharmaceuticals
  32. Schering Plough
  33. Shire Pharmaceuticals
  34. Sigmoid Pharma
  35. Teva Pharmaceuticals
  36. UCB Pharma
  37. Falk
  38. Merck
  39. Jansen
  40. Shire
  41. UCB

Ask authors/readers for more resources

Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum, resulting from a dysregulated immune response towards intraluminal antigens in a genetically predisposed host. The disease has a varying extent and severity. Approximately 20% of patients with ulcerative colitis experience a severe flare during the course of their disease, requiring hospitalization. Acute severe ulcerative colitis (ASUC) is potentially a life-threatening condition that requires early recognition, hospitalization, correction of body fluids and electrolytes, and nutritional support if needed. Superimposed bacterial or viral infections need to be excluded and thromboprophylaxis should be started. Intravenous corticosteroids are the first-line treatment for this condition. Rescue treatment with ciclosporin or infliximab is indicated in patients who do not sufficiently respond to corticosteroids after 3-5 days, with close monitoring of the patients' symptoms, serum C-reactive protein and albumin levels. If medical therapy fails, timely colectomy should be performed to prevent critical complications. In this article, we review all relevant aspects of ASUC, from its pathophysiological background to modern management in clinical practice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available